Next Generation Sequencing for Cancer Diagnostics
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Informatics and Big Data".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 1222
Special Issue Editor
Interests: next generation sequencing (NGS)-based assay development; diagnostic clinical oncology; genomic characterization of solid tumors and hematologic malignancies; using genomic data for patient stratification into treatment groups; monitoring response to treatment
Special Issue Information
Dear Colleagues,
Cancer is a leading cause of death worldwide, and accounted for ~10 million cancer deaths in 2020. The introduction of next-generation sequencing (NGS) technologies in clinical oncology laboratories has allowed the detection of somatic alterations, including single nucleotide variants, small indels, copy number variants and structural variants, on a genome-wide scale. Large-scale sequencing studies have illustrated the genomic landscapes of different cancers, thus leading to the identification of novel driver mutations, prognostic markers and a large number of therapeutic targets. Recent progress in genomic analysis using NGS technology has enabled the comprehensive detection of mutations, as well as the tumor mutation burden (TMB), in patient tumors, a biomarker for immunotherapy. NGS-based techniques have also been applied at the transcriptomic and epigenomic levels in order to accelerate our understanding of cancer biology and clinical trials for novel therapeutics. Precision medicine has revolutionized the therapeutic management of cancer patients, which is driven by the sequencing of circulating tumor DNA (ctDNA) from liquid biopsies. This has allowed targeted therapy to be developed, by monitoring patient responses to treatment and identifying the eventual genomic mechanisms of resistance. NGS-based technologies have played a significant role in the stratification of patients for targeted therapy based on specific molecular alterations, which are detected in the tissue biopsy or in the liquid biopsy; they have therefore become increasingly part of routine clinical practice. In this issue of Cancers, we would like to present a review of the currently available data on the utility of NGS-based applications for cancer diagnostics.
Dr. Gayatry Mohapatra
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- next-generation sequencing
- liquid biopsy
- transcriptome
- epigenome
- targeted therapy
